Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Published in: Journal of Neurology 1/2018

01-01-2018 | Original Communication

A new measure for end of life planning, preparation, and preferences in Huntington disease: HDQLIFE end of life planning

Authors: Noelle E. Carlozzi, E. A. Hahn, S. A. Frank, J. S. Perlmutter, N. D. Downing, M. K. McCormack, S. Barton, M. A. Nance, S. G. Schilling, HDQLIFE Site Investigators and Coordinators

Published in: Journal of Neurology | Issue 1/2018

Login to get access

Abstract

Background

Huntington disease is a fatal inherited neurodegenerative disease. Because the end result of Huntington disease is death due to Huntington disease-related causes, there is a need for better understanding and caring for individuals at their end of life.

Aim

The purpose of this study was to develop a new measure to evaluate end of life planning.

Design

We conducted qualitative focus groups, solicited expert input, and completed a literature review to develop a 16-item measure to evaluate important aspects of end of life planning for Huntington disease. Item response theory and differential item functioning analyses were utilized to examine the psychometric properties of items; exploratory factor analysis was used to establish meaningful subscales.

Participants

Participants included 508 individuals with pre-manifest or manifest Huntington disease.

Results

Item response theory supported the retention of all 16 items on the huntington disease quality of life (“HDQLIFE”) end of life planning measure. Exploratory factor analysis supported a four-factor structure: legal planning, financial planning, preferences for hospice care, and preferences for conditions (locations, surroundings, etc.) at the time of death. Although a handful of items exhibited some evidence of differential item functioning, these items were retained due to their relevant clinical content. The final 16-item scale includes an overall total score and four subscale scores that reflect the different end of life planning constructs.

Conclusions

The 16-item HDQLIFE end of life planning measure demonstrates adequate psychometric properties; it may be a useful tool for clinicians to clarify patients’ preferences about end of life care.
Appendix
Available only for authorised users
Literature
1.
Nance MA, Sanders G (1996) Characteristics of individuals with Huntington disease in long-term care. Mov Disord 11(5):542–548CrossRefPubMed
2.
Kirwin JL, Edwards RA (2013) Helping patients articulate end-of-life wishes: a target for interprofessional participation. Ann Palliat Med 2(2):95–97PubMed
3.
Booij SJ et al (2014) Thinking about the end of life: a common issue for patients with Huntington’s disease. J Neurol 261(11):2184–2191CrossRefPubMed
4.
Booij SJ et al (2013) A plea for end-of-life discussions with patients suffering from Huntington’s disease: the role of the physician. J Med Ethics 39(10):621–624CrossRefPubMed
5.
Booij SJ et al (2014) Perhaps the subject of the questionnaire was too sensitive: Do we expect too much too soon? Wishes for the end of life in Huntington’s Disease—the perspective of European physicians. J Huntingtons Dis 3(3):229–232PubMed
6.
7.
Dellefield ME, Ferrini R (2011) Promoting excellence in end-of-life care: lessons learned from a cohort of nursing home residents with advanced Huntington disease. J Neurosci Nurs 43(4):186–192CrossRefPubMed
8.
Dubinsky R et al (2004) Lifting the veil of Huntington’s disease: Recommendations to the field from the Huntington’s disease Peer Workgroup. Roberrt Wood Johnson Foundation, Princeton
9.
Klager J et al (2008) Huntington’s disease: a caring approach to the end of life. Care Manag J 9(2):75–81CrossRefPubMed
10.
Mullahy CM, Jensen DK (2005) End-of-life care: a special calling for case managers. Case Manag 16(1):40–42
11.
12.
Carlozzi NE, Tulsky DS (2012) Identification of health-related quality of life (HRQOL) issues relevant to individuals with Huntington disease. J Health Psychol
13.
14.
Booij SJ et al (2013) Euthanasia and physician-assisted suicide in Huntington’s disease in The Netherlands. Int Psychogeriatr 25(2):339–340CrossRefPubMed
15.
Perkins HS (2007) Controlling death: the false promise of advance directives. Ann Intern Med 147(1):51–57CrossRefPubMed
16.
17.
Voogt E et al (2005) Attitudes of patients with incurable cancer toward medical treatment in the last phase of life. J Clin Oncol 23(9):2012–2019CrossRefPubMed
18.
Lyon ME et al (2014) A longitudinal, randomized, controlled trial of advance care planning for teens with cancer: anxiety, depression, quality of life, advance directives, spirituality. J Adolesc Health 54(6):710–717CrossRefPubMed
19.
Brinkman-Stoppelenburg A, Rietjens JA, van der Heide A (2014) The effects of advance care planning on end-of-life care: a systematic review. Palliat Med 28(8):1000–1025CrossRefPubMed
20.
Paulsen JS et al (2006) Preparing for preventive clinical trials: the predict-HD study. Arch Neurol 63(6):883–890CrossRefPubMed
21.
Paulsen JS et al (2008) Detection of Huntington’s disease decades before diagnosis: the predict-HD study. J Neurol Neurosurg Psychiatry 79(8):874–880CrossRefPubMed
22.
Paulsen JS et al (2014) Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study. Front Aging Neurosci 6:78CrossRefPubMedPubMedCentral
23.
Hanauer DA et al (2015) Supporting information retrieval from electronic health records: a report of University of Michigan’s nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE). J Biomed Inform 55:290–300CrossRefPubMedPubMedCentral
24.
Carlozzi NE et al (2016) HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). Qual Life Res 25(10):2441–2455CrossRefPubMed
25.
Carlozzi NE, Tulsky DS (2013) Identification of health-related quality of life (HRQOL) issues relevant to individuals with Huntington disease. J Health Psychol 18(2):212–225CrossRefPubMed
26.
MetaMetrics (1995) The LEXILE framework for reading. MetaMetrics Inc, Durham
27.
Huntington Study Group (1996) Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 11(2):136–142CrossRef
28.
29.
Marder K et al (2000) Rate of functional decline in Huntington’s disease. Huntington Study Group. Neurology 54(2):452–458CrossRefPubMed
30.
Samejima F, van der Liden WJ, Hambleton R (1996) The graded response model. In: van der Liden WJ (ed) Handbook of modern item response theory. Springer, NY, pp 85–100
31.
Cai L, Thissen D, du Toit SHC (2011) IRTPRO for Windows [Computer software]. Scientific Software International, Lincolnwood
32.
van der Linden WJ, Hambleton RK (1997) Handbook of modern item response theory. Springer, New YorkCrossRef
33.
Crane PK et al (2006) Differential item functioning analysis with ordinal logistic regression techniques. DIFdetect and difwithpar. Med Care 44(11 Suppl 3):S115–S123CrossRefPubMed
34.
Kline RB (2005) Principles and practice of structural equation modeling, 2nd edn. Guilford Press, New York
35.
36.
Hu LT, Bentler PM (1999) Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model Multidiscip J 6(1):1–55CrossRef
37.
Hatcher L (1994) A step-by-step approach to using SAS for factor analysis and structural equation modeling. SAS Institute Inc, Cary
38.
McDonald RP (1999) Test theory: a unified treatment. Lawrence Erlbaum Associates Inc, Mahwah
39.
Reise SP, Morizot J, Hays RD (2007) The role of the bifactor model in resolving dimensionality issues in health outcomes measures. Qual Life Res 16(Suppl 1):19–31CrossRefPubMed
40.
Cook KF, Kallen MA, Amtmann D (2009) Having a fit: impact of number of items and distribution of data on traditional criteria for assessing IRT’s unidimensionality assumption. Qual Life Res 18(4):447–460CrossRefPubMedPubMedCentral
41.
Muthén LK, Muthén BO (2011) Mplus User’s Guide. Muthén & Muthén, Los Angeles
42.
Carlozzi NE et al (2016) HDQLIFE: the development of two new computer adaptive tests for use in Huntington disease, Speech Difficulties, and Swallowing Difficulties. Qual Life Res 25(10):2417–2424CrossRefPubMedPubMedCentral
43.
Carlozzi NE et al (2016) The development of a new computer adaptive test to evaluate chorea in Huntington disease: HDQLIFE Chorea. Qual Life Res 25(10):2429–2439CrossRefPubMedPubMedCentral
44.
Carlozzi NE et al (2016) New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement system). Qual Life Res 25(10):2403–2415CrossRefPubMedPubMedCentral
45.
Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Academic Press, New York
46.
DeVellis R (2017) Scale development: theory and applications. In: Bickman L, Rog DJ (eds) Applied social research methods series, 4th edn. Sage, Los Angeles
47.
48.
Zhang Y et al (2011) Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am J Med Genet Part B Neuropsychiatr Genet 156B(7):751–763CrossRef
Metadata
Title
A new measure for end of life planning, preparation, and preferences in Huntington disease: HDQLIFE end of life planning
Authors
Noelle E. Carlozzi
E. A. Hahn
S. A. Frank
J. S. Perlmutter
N. D. Downing
M. K. McCormack
S. Barton
M. A. Nance
S. G. Schilling
HDQLIFE Site Investigators and Coordinators
Publication date
01-01-2018
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 1/2018
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-017-8677-7

Other articles of this Issue 1/2018

Journal of Neurology 1/2018 Go to the issue

Short Commentary

The medial vestibular nuclei, a vulnerable target in thiamine deficiency

Original Communication

CXCL13 as a diagnostic marker of neuroborreliosis and other neuroinflammatory disorders in an unselected group of patients

Correction

Correction to: Blood lymphocyte subsets identify optimal responders to IFN-beta in MS

Original Communication

Contribution of EEG in transient neurological deficits

Original Communication

Anti-MAG associated cerebellar ataxia and response to rituximab

Original Communication

Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan